Yong Yu - May 29, 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Thomas Zindrick, J.D., Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
May 29, 2024
Transactions value $
$0
Form type
4
Date filed
6/7/2024, 09:40 PM
Previous filing
Jul 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Purchase +2.5K 2.5K May 29, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Common Stock Warrant (Right to Buy) Purchase +2.5K 2.5K May 29, 2024 Common Stock 2.5K $5.25 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs.
F2 The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.